Rep. Kim Schrier

Magnet Injury Prevention Act This bill prohibits as hazardous consumer products specified small, high-powered magnets. The prohibition includes magnets that (1) are designed and marketed for entertainment or mental stimulation (e.g., puzzle working, sculpture building, or certain jewelry); (2) are not classified as a toy or children’s jewelry subject to existing standards; (3) pose a choking, aspiration, or ingestion risk to young children; and (4) have a magnetic field magnitude above a certain threshold. The bill also authorizes the Consumer Product Safety Commission to issue product safety standards for certain other types of small, high-powered magnets.

My Body, My Data Act of 2022 This bill establishes protections, subject to certain limits, for personal reproductive or sexual health information. This includes information relating to past, present, or future surgeries or procedures, such as the termination of a pregnancy. Specifically, commercial entities, including individuals, nonprofits, and common carriers, may not collect, retain, use, or disclose personal reproductive or sexual health information except (1) with the express written consent of the individual to whom such information relates, or (2) as is strictly necessary to provide a requested product or service. Commercial entities also must provide individuals with access to, and a reasonable mechanism to delete, any of their reproductive or sexual health information upon request. Further, commercial entities must maintain and publish a privacy policy describing their practices with respect to such information. The bill's provisions do not apply to entities that are subject to certain existing health-related privacy regulations, such as the privacy regulations issued under the Health Insurance Portability and Accountability Act of 1996. Additionally, the provisions do not apply to the disclosure of personal reproductive or sexual health information for the publication of newsworthy information of legitimate public concern. The bill provides for enforcement by the Federal Trade Commission and by private civil actions.

Advanced Research Project s Agency-Health Act or the ARPA-H Act This bill establishes within the Department of Health and Human Services (HHS) the Advanced Research Projects Agency-Health to accelerate health and medical innovation by investing in high-risk, high-reward research. The bill also establishes a committee to advise on agency activities. HHS must transfer all authorities, functions, funds, and personnel from a similar entity within the National Institutes of Health to a new, independent agency. Additionally, the President must appoint a director to lead the agency. The director may submit testimony and recommendations concerning the agency to Congress without review or approval by other federal officers or agencies. The director must appoint personnel to administer the agency's research programs, including by selecting projects to support and making recommendations about terminating or continuing projects. The agency may use grants, prize competitions, and a variety of other mechanisms to support the research projects. The agency's budget is separate from that of HHS. The agency must coordinate with the Food and Drug Administration and the Centers for Medicare & Medicaid Services to expedite development and coverage of high-need cures. Additionally, the agency may partner with other public and private entities (e.g., institutions of higher education and patient advocacy organizations). The bill also requires the agency to develop and periodically update a strategic plan and annually report on its activities. Furthermore, (1) the National Academies of Sciences, Engineering, and Medicine must evaluate the agency's performance; and (2) the Government Accountability Office must review the research portfolio of HHS and its components, including the new agency.

Improving Diagnosis in Medicine Act of 2022 This bill requires various activities to improve diagnostic safety and quality in health care. The Department of Health and Human Services (HHS) must convene an expert panel to make recommendations about the data needed to accelerate diagnostic safety and quality research. In convening the panel, HHS must coordinate with the Agency for Healthcare Research and Quality (AHRQ), the Centers for Medicare & Medicaid Services, and other HHS components. HHS must also establish an interagency council to develop a strategic plan and recommendations to improve diagnosis in health care. In addition, AHRQ must (1) establish a quality improvement program related to diagnostic errors that includes dissemination of evidence-based strategies to improve diagnostic quality, safety, and health-care value; and (2) seek to contract with the National Academies of Sciences, Engineering, and Medicine to study disparities in diagnostic safety and quality. The bill also allows specified grants provided by AHRQ and by the National Institutes of Health to be used for diagnostic safety and quality research.

Water Infrastructure Finance and Innovation Act Amendments of 2022 This bill expands and modifies the Water Infrastructure and Innovation Act (WIFIA) loan program by, for example, expanding eligibility to state water storage projects, transferred works, and certain nonfederally owned projects. WIFIA provides credit assistance through secured or direct loans for water infrastructure projects.

Recovering America’s Wildlife Act of 2022 This bill provides funding for the conservation or restoration of wildlife and plant species of greatest conservation need, including endangered or threatened species, and establishes related requirements. TITLE I--WILDLIFE CONSERVATION AND RESTORATION (Sec. 101) This title establishes and funds a subaccount of the Wildlife Conservation and Restoration Account, which was established under the Pittman-Robertson Wildlife Restoration Act. The subaccount must be used to support efforts of states, territories, or the District of Columbia to recover and manage wildlife and plant species of greatest conservation need. The Department of the Interior must use a portion of the funding from the subaccount for grants to state fish and wildlife departments, the District of Columbia fish and wildlife department, fish and wildlife departments of territories, nonprofit organizations, or regional associations of fish and wildlife departments. The grants must be used for innovative recovery efforts for species of greatest conservation need, species listed as endangered or threatened species, or the habitats of such species. Funding for the subaccount must supplement existing funds available to the states from funds distributed under the Dingell-Johnson Sport Fish Restoration Act and the Wildlife Conservation and Restoration Account. Recipients of the funding from the subaccount must match federal funds as specified by the title. The Government Accountability Office must study and report on the progress of states, territories, the District of Columbia, and Indian tribes in protecting species of greatest conservation need, endangered species, and threatened species. TITLE II--TRIBAL WILDLIFE CONSERVATION AND RESTORATION (Sec. 201) This title establishes and funds a Tribal Wildlife Conservation and Restoration Account to support Indian tribes' efforts to recover and manage wildlife and plant species of greatest conservation need. Indian tribes are not required to provide matching funds. TITLE III--ENDANGERED SPECIES RECOVERY AND HABITAT CONSERVATION LEGACY FUND (Sec. 301) This title establishes and funds through FY2026 the Endangered Species Recovery and Habitat Conservation Legacy Fund. The U.S. Fish and Wildlife Service must use the fund to (1) implement an Endangered Species Recovery Grant Program; (2) address its interagency consultation responsibilities under the Endangered Species Act of 1973; (3) work with nonfederal entities to conserve wildlife habitat and at-risk species, threatened or endangered species, or species proposed to be listed as threatened or endangered species; or (4) address the development and permitting of voluntary conservation agreements under such act. Amounts made available under the fund must supplement other federal amounts made available to carry out such activities. The President must annually submit to Congress, together with the annual budget of the United States, a list of threatened species and endangered species for which recovery plans will be developed or implemented with amounts from the Endangered Species Recovery and Habitat Conservation Legacy Fund. TITLE IV--REPORT (Sec. 401) Interior must also report on information concerning the amount of grants and contracts that were awarded or are allocated under this bill to Historically Black Colleges and Universities, Hispanic-serving educational institutions, tribally controlled colleges and universities, minority-serving educational institutions, minority-owned business enterprises, women-owned business enterprises, and community-based organizations that are principally administered by, operated by, or serving minority communities.

Formula Shortage Reporting Act of 2022 This bill requires manufacturers of infant formula to notify the Food and Drug Administration (FDA) at least 72 hours in advance of a manufacturing interruption or product discontinuance that is expected to meaningfully disrupt the product's supply. The FDA must post such information on its website and notify health care providers.

Military Spouse Hiring Act This bill expands the Work Opportunity Tax Credit (WOTC) to include the hiring of a qualified military spouse. (The WOTC permits employers who hire individuals who are members of a targeted group such as qualified veterans, ex-felons, or long-term unemployment recipients to claim a tax credit equal to a portion of the wages paid to those individuals.) A qualified military spouse is any individual who is certified by the designated local agency as being (as of the hiring date) a spouse of a member of the Armed Forces.

Protecting Infants from Formula Shortages Act of 2022 This bill imposes requirements on manufacturers of infant formula and medical foods for individuals with inborn errors of metabolism. A manufacturer of such a food must notify the Food and Drug Administration (FDA) of any circumstance that is likely to lead to a meaningful disruption of the U.S. supply of the food, including a discontinuance or interruption of manufacturing. The manufacturer must submit the notification at least six months prior to the cause of the disruption or, if that is not possible, as soon as practicable. The FDA must provide the Department of Agriculture and appropriate organizations information about the cause of the disruption. The FDA must inform a person (an individual or entity) of their failure to comply with these notification requirements. If the failure continues for a certain time period, the person shall be subject to fines, imprisonment, or both. During a public health emergency, the FDA may impose additional conditions for such notifications and designate additional categories of food that are subject to the notification requirements. The bill also requires each manufacturer of such a food to develop and maintain a redundancy risk management plan that identifies and evaluates risks for each manufacturing establishment for the food.

Keep Infant Formula Safe and On the Shelves Act of 2022 This bill requires the Food and Drug Administration (FDA) to periodically inspect infant formula manufacturing facilities and addresses related issues. The FDA must periodically conduct inspections, including unannounced inspections, of infant formula manufacturer facilities. If the FDA makes a notable regulatory finding at such a facility, the manufacturer must undergo a comprehensive food safety audit that includes a root cause analysis, enhanced testing, and comprehensive environmental samples. A manufacturer of infant formula or essential medical food must notify the FDA no later than five business days after becoming aware of circumstances that could lead to a shortage of the relevant product in the United States. Further, the FDA must create and annually update a list of U.S. manufacturing facilities that could be converted to manufacture infant formula during a shortage. In the event of a shortage, the FDA may require infant formula manufacturers to provide certain information, such as the quantity of formula in a manufacturer's inventory. The bill also establishes under statute that food, including infant formula, is a critical material essential to the national defense and therefore subject to authorities under the Defense Production Act of 1950. (Such authorities authorize the President to take various actions, such as requiring businesses to prioritize certain government contracts and incentivizing the domestic industrial base to expand the production of critical materials.) The Occupational Safety and Health Administration must issue a fact sheet and provide technical assistance to infant formula manufacturers to promote compliance with occupational health and safety standards.